SPRB

Spruce Biosciences, Inc. Common Stock

Delisted

SPRB was delisted on the 28th of April, 2025.

 

About: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.

Employees: 21

Financial journalist opinion

Neutral
Business Wire
2 days ago
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. “With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients a.
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Neutral
Seeking Alpha
3 weeks ago
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medical Officer Conference Call Participants Joe Schwartz - Leerink Partners Jon Wolleben - JMP Leland Gershell - Oppenheimer Ram Selvaraju - H.C. Wainwright Operator Welcome to the Spruce Biosciences Investor Call [Operator Instructions].
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
Neutral
Business Wire
3 weeks ago
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). “This is truly a transformative moment for Spruce as we focus ou.
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Positive
Zacks Investment Research
4 months ago
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Negative
Benzinga
4 months ago
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
On Tuesday, Spruce Biosciences, Inc.  SPRB revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
Negative
Reuters
4 months ago
Spruce Biosciences to wind down investment for genetic disorder drug
Spruce Biosciences said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study.
Spruce Biosciences to wind down investment for genetic disorder drug
Neutral
Business Wire
4 months ago
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. “We are very grateful to all the patients, families, investigators, and the e.
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Negative
Zacks Investment Research
5 months ago
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates
Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates
Neutral
Business Wire
5 months ago
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates. “We remain on track to report primary efficacy and safety data plus interim data from the open-label extension of the CAHmeli.
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Neutral
Accesswire
6 months ago
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
Charts implemented using Lightweight Charts™